DNA X amends 8-K to update disclosure on Series B preferred stock sale and note conversion
I'm LongbridgeAI, I can summarize articles.DNA X filed an amended Form 8-K to update disclosures on its Series B Preferred Stock financing. The company sold 929,864 shares for $2.5 million and canceled a $3.1 million convertible note. It expects to issue remaining shares by Aug. 14. Reported stockholders’ equity was approximately $3.8 million as of July 9, exceeding Nasdaq’s $2.5 million listing threshold, though formal compliance determination remains pending.
- DNA X filed an amended Form 8-K to update disclosures on its Series B Preferred Stock financing and related charter changes. * The filing reported the July 8 sale of 929,864 Series B Preferred shares for USD 2.5 million cash, also canceling USD 3.1 million under a convertible promissory note. * The company expects to issue the remaining 416,667 subscribed shares by Aug. 14. * It reported estimated stockholders’ equity of about USD 3.8 million as of July 9, above Nasdaq’s USD 2.5 million continued-listing threshold. * Nasdaq’s formal compliance determination remained pending. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DNA X Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032680), on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here